form8-k_052010.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 20, 2010
Emergent BioSolutions Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
001-33137
|
14-1902018
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
2273 Research Boulevard, Suite 400, Rockville, Maryland
|
20850
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (301) 795-1800
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
Emergent BioSolutions Inc. (the “Company”) held its 2010 Annual Meeting of Stockholders on May 20, 2010. The stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement dated April 8, 2010.
Proposal 1: The election of Fuad El-Hibri, Jerome M. Hauer and Ronald B. Richard to serve as Class I directors, each for a term of three years. The votes were cast as follows:
|
Nominees
|
For
|
Withheld
|
|
Fuad El-Hibri
|
26,159,296
|
344,848
|
|
Jerome M. Hauer
|
25,952,859
|
551,285
|
|
Ronald B. Richard
|
24,217,928
|
2,287,116
|
All directors were duly elected.
Proposal 2: The ratification of the selection by the audit committee of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2010.
|
For
|
Against
|
Abstaining
|
|
27,997,971
|
213,282
|
19,595
|
Proposal 2 was approved.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: May 26, 2010
|
EMERGENT BIOSOLUTIONS INC.
|
| |
By:
|
/s/ R. Don Elsey
R. Don Elsey
Chief Financial Officer
|